STAGE IV COLON CANCER AJCC V8
Clinical trials for STAGE IV COLON CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV COLON CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV COLON CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat colorectal cancer: drug duo targets tumor defenses
Disease control OngoingThis study tests a combination of two drugs—SX-682 and nivolumab—in people with a specific type of advanced colorectal cancer (RAS-mutated, MSS) that has spread or can't be removed. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 51…
Matched conditions: STAGE IV COLON CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 06:50 UTC
-
New hope for tough-to-treat colon cancer? drug cocktail enters human trials
Disease control OngoingThis early-stage trial tests a combination of chemotherapy (FOLFOX), a blood-vessel blocker (bevacizumab), and two immunotherapy drugs (botensilimab and balstilimab) in 20 people with a type of advanced colorectal cancer called MSS that has spread. The goal is to see if this mix …
Matched conditions: STAGE IV COLON CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
New drug cocktail shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis study tests whether adding two targeted drugs (LY3214996 and abemaciclib) to the standard drug cetuximab can shrink tumors or slow cancer growth in people with advanced colorectal cancer that no longer responds to cetuximab alone. About 46 adults with metastatic or inoperabl…
Matched conditions: STAGE IV COLON CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New combo therapy targets hard-to-treat HER2 cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a cell-growth blocker)—in people with advanced solid tumors that have a HER2 mutation. The study first finds the safest dose, then compares the combo against…
Matched conditions: STAGE IV COLON CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
Immunotherapy boost may tame tough colorectal cancer
Disease control OngoingThis study is for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E) and has not responded to prior treatment. It compares the usual two-drug therapy (encorafenib and cetuximab) against the same two drugs plus an immunotherapy drug called nivol…
Matched conditions: STAGE IV COLON CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:19 UTC